Needham Reiterates Buy on Recursion Pharmaceuticals, Maintains $17 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Gil Blum has reiterated a 'Buy' rating on Recursion Pharmaceuticals (NASDAQ:RXRX) and maintained a price target of $17.
July 12, 2023 | 5:23 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Needham analyst has reiterated a 'Buy' rating on Recursion Pharmaceuticals and maintained a price target of $17.
The reiteration of a 'Buy' rating by a Needham analyst indicates a positive outlook for Recursion Pharmaceuticals. The maintained price target of $17 suggests that the analyst believes the stock is undervalued at current levels, which could lead to upward price movement in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100